Autres langues Nirvana Life Sciences Inc.

Actions

NIRV

CA6546521064

Temps Différé Canadian Securities Exchange Autres places de cotation 21:01:35 22/05/2024			Varia. 5j.	Varia. 1 janv.
0,04 ^CAD	-20,00 %		-.--%	+100,00 %

02/04	Nirvana Life Sciences Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 31 janvier 2024	CI
02/01	Nirvana Life Sciences Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 octobre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	02/04
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	02/01
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	01/11
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	28/10/23
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc.	31/07/23
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	03/04/23
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors	22/02/23
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	31/12/22
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors	09/11/22
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022	29/09/22
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds	07/09/22
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	29/08/22
Nirvana Life Sciences Inc. Announces License for A Delivery System for Psychedelic APIs	06/07/22
Nirvana Life Sciences Announces Approval to Build Vancouver Facility from Health Canada	28/06/22
Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug Compound	23/06/22
Nirvana Life Sciences Announces Patent Filing	09/06/22
Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study	02/06/22
Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory Board	05/04/22
Nirvana Life Sciences Inc. Announce Further Progress with Development of Its Vancouver Research and Development Facility	25/03/22
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	16/03/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nirvana Life Sciences Inc.

Actions

NIRV

CA6546521064

Autres langues

Filtres